Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study
- PMID: 35469360
- PMCID: PMC9037582
- DOI: 10.1007/s11606-022-07603-4
Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study
Abstract
Background: Disparities in access to anti-SARS-CoV-2 monoclonal antibodies have not been well characterized.
Objective: We sought to explore the impact of race/ethnicity as a social construct on monoclonal antibody delivery.
Design/patients: Following implementation of a centralized infusion program at a large academic healthcare system, we reviewed a random sample of high-risk ambulatory adult patients with COVID-19 referred for monoclonal antibody therapy.
Main measures: We examined the relationship between treatment delivery, race/ethnicity, and other demographics using descriptive statistics, binary logistic regression, and spatial analysis.
Key results: There was no significant difference in racial composition between patients who did (n = 25) and patients who did not (n = 378) decline treatment (p = 0.638). Of patients who did not decline treatment, 64.8% identified as White, 14.8% as Hispanic/Latinx, and 11.1% as Black. Only 44.6% of Hispanic/Latinx and 31.0% of Black patients received treatment compared to 64.1% of White patients (OR 0.45, 95% CI 0.25-0.81, p = 0.008, and OR 0.25, 95% CI 0.12-0.50, p < 0.001, respectively). In multivariable analysis including age, race, insurance status, non-English primary language, county Social Vulnerability Index, illness severity, and total number of comorbidities, associations between receiving treatment and Hispanic/Latinx or Black race were no longer statistically significant (AOR 1.32, 95% CI 0.69-2.53, p = 0.400, and AOR 1.34, 95% CI 0.64-2.80, p = 0.439, respectively). However, patients who were uninsured or whose primary language was not English were less likely to receive treatment (AOR 0.16, 95% CI 0.03-0.88, p = 0.035, and AOR 0.37, 95% CI 0.15-0.90, p = 0.028, respectively). Spatial analysis suggested decreased monoclonal antibody delivery to Cook County patients residing in socially vulnerable communities.
Conclusions: High-risk ambulatory patients with COVID-19 who identified as Hispanic/Latinx or Black were less likely to receive monoclonal antibody therapy in univariate analysis, a finding not explained by patient refusal. Multivariable and spatial analyses suggested insurance status, language, and social vulnerability contributed to racial disparities.
Keywords: COVID-19; SARS-CoV-2; Social Vulnerability Index; monoclonal antibody; racial/ethnic disparities.
© 2022. The Author(s), under exclusive licence to Society of General Internal Medicine.
Conflict of interest statement
V. Stosor reports research support, paid to Northwestern University, from Eli Lilly and Company. M. G. Ison reports research support, paid to Northwestern University, from GlaxoSmithKline and Regeneron.
Figures
Similar articles
-
Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.JAMA Netw Open. 2020 May 1;3(5):e205734. doi: 10.1001/jamanetworkopen.2020.5734. JAMA Netw Open. 2020. PMID: 32453384 Free PMC article.
-
County-level barriers in the COVID-19 vaccine coverage index and their associations with willingness to receive the COVID-19 vaccine across racial/ethnic groups in the U.S.Front Public Health. 2023 Oct 12;11:1192748. doi: 10.3389/fpubh.2023.1192748. eCollection 2023. Front Public Health. 2023. PMID: 37900019 Free PMC article.
-
Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic.JAMA Netw Open. 2020 Dec 1;3(12):e2031640. doi: 10.1001/jamanetworkopen.2020.31640. JAMA Netw Open. 2020. PMID: 33372974 Free PMC article.
-
Racial Disparities in Mortality Associated With Acute Myocardial Infarction and COVID-19 in the United States: A Nationwide Analysis.Curr Probl Cardiol. 2023 Sep;48(9):101798. doi: 10.1016/j.cpcardiol.2023.101798. Epub 2023 May 11. Curr Probl Cardiol. 2023. PMID: 37178989 Free PMC article. Review.
-
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients.Front Immunol. 2023 May 5;14:1172993. doi: 10.3389/fimmu.2023.1172993. eCollection 2023. Front Immunol. 2023. PMID: 37215103 Free PMC article. Review.
Cited by
-
Health Equity and Access to COVID-19 Treatments Available through Emergency Use Authorizations.J Racial Ethn Health Disparities. 2024 Jul 22. doi: 10.1007/s40615-024-02094-x. Online ahead of print. J Racial Ethn Health Disparities. 2024. PMID: 39039261
-
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. eCollection 2024. Pathog Immun. 2024. PMID: 38746756 Free PMC article.
-
Effect of Paxlovid Treatment During Acute COVID-19 on Long COVID Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER Consortia.medRxiv [Preprint]. 2024 Jul 31:2024.01.20.24301525. doi: 10.1101/2024.01.20.24301525. medRxiv. 2024. PMID: 38343863 Free PMC article. Preprint.
-
Breaking Barriers: A Single-Center Real-World Experience With Recruitment and Administration of COVID-19 Monoclonal Antibodies and Opportunities for Improvement.Open Forum Infect Dis. 2023 Dec 26;11(2):ofad665. doi: 10.1093/ofid/ofad665. eCollection 2024 Feb. Open Forum Infect Dis. 2023. PMID: 38328493 Free PMC article.
-
The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.J Gen Intern Med. 2023 Dec;38(16):3472-3481. doi: 10.1007/s11606-023-08324-y. Epub 2023 Sep 15. J Gen Intern Med. 2023. PMID: 37715096
References
-
- Eli Lilly and Company. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. U.S. Food and Drug Administration; 2021 [cited 2021 Oct 1]. Available from: https://www.fda.gov/media/145802/download.
-
- Regeneron Pharmaceuticals, Inc. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of REGEN-COVTM (casirivimab and imdevimab). U.S. Food and Drug Administration; 2021 [cited 2021 Oct 1]. Available from: https://www.fda.gov/media/145611/download.
-
- GlaxoSmithKline. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Sotrovimab. U.S. Food and Drug Administration; 2021 [cited 2021 Oct 1]. Available from: https://www.fda.gov/media/149534/download.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous